Regenxbio Inc (RGNX)
9.18
-0.45
(-4.67%)
USD |
NASDAQ |
Nov 21, 16:00
9.26
+0.08
(+0.87%)
Pre-Market: 08:34
Regenxbio Gross Profit Margin (Quarterly): 48.81% for Sept. 30, 2024
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 48.81% |
| June 30, 2024 | 52.55% |
| March 31, 2024 | 72.58% |
| December 31, 2023 | 49.41% |
| September 30, 2023 | 57.16% |
| June 30, 2023 | 52.57% |
| March 31, 2023 | 78.51% |
| December 31, 2022 | 59.22% |
| September 30, 2022 | 50.61% |
| June 30, 2022 | 60.33% |
| March 31, 2022 | 29.26% |
| December 31, 2021 | 94.22% |
| September 30, 2021 | 54.16% |
| June 30, 2021 | 55.44% |
| March 31, 2021 | 74.31% |
| December 31, 2020 | 52.17% |
| September 30, 2020 | 82.44% |
| June 30, 2020 | 71.73% |
| March 31, 2020 | 80.68% |
| December 31, 2019 | 67.79% |
| September 30, 2019 | 83.03% |
| Date | Value |
|---|---|
| June 30, 2019 | 75.55% |
| March 31, 2019 | 96.72% |
| December 31, 2018 | 93.03% |
| September 30, 2018 | 90.26% |
| June 30, 2018 | 90.33% |
| March 31, 2018 | 98.18% |
| December 31, 2017 | |
| September 30, 2017 | 48.88% |
| June 30, 2017 | 79.93% |
| March 31, 2017 | 80.00% |
| December 31, 2016 | 80.54% |
| September 30, 2016 | 72.00% |
| June 30, 2016 | 79.03% |
| March 31, 2016 | 75.57% |
| December 31, 2015 | 80.17% |
| September 30, 2015 | 77.46% |
| June 30, 2015 | 77.26% |
| March 31, 2015 | 91.77% |
| December 31, 2014 | 86.85% |
| September 30, 2014 | 97.52% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
29.26%
Minimum
Mar 2022
94.22%
Maximum
Dec 2021
62.20%
Average
58.19%
Median
Gross Profit Margin (Quarterly) Benchmarks
| Catalyst Pharmaceuticals Inc | 85.02% |
| EyePoint Pharmaceuticals Inc | 93.01% |
| Cassava Sciences Inc | -- |
| Vertex Pharmaceuticals Inc | 85.84% |
| Sarepta Therapeutics Inc | 80.37% |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | -69.61% |
| Return on Assets | -40.81% |
| Return on Invested Capital | -69.61% |
| Profit Margin (Quarterly) | -246.3% |
| Operating Margin (Quarterly) | -256.6% |
| Return on Net Operating Assets | -106.8% |